13th June 2022 | Pharma Updates

GSK Velu in talks with investors, private equity firms & banks to buy back Metropolis Healthcare

GSK Velu is considering a bid for Metropolis Healthcare, a company he once co-founded with the Shah family, seven years after selling his stake due to a boardroom feud.

Aurobindo Pharma facing an epilepsy drug lawsuit in US

Japanese pharma giant Eisai, and Swiss pharma biggie Novartis Pharma AG have taken Hyderabad-based Aurobindo Pharma to court in the United States, alleging patent infringement of their anti-epilepsy drug Banzel.

GSK getting closer to developing vaccine for common respiratory virus

GSK intends to submit its respiratory syncytial virus vaccine to regulators for review later this year, after interim data from a closely watched late-stage study involving older adults showed the vaccine was effective.

Evegen Pharma and Michigan University collaborate on a colorectal cancer study

Dr. Grace Chen of the University of Michigan will collaborate with Evgen Pharma to investigate the potential anti-tumor effects of its lead asset, SFX-01, on colorectal cancer (CRC).

Strides Pharma recalls over 6 lakh bottles of blood pressure medication in US

USFDA enforcement report, the company, a unit of Bengaluru-headquartered Strides Pharma Science, is recalling 6,78,829 bottles of the blood pressure lowering drug in the US market.

Market for hyperphosphatemia drugs might see a significant shift

The global Hyperphosphatemia Drugs industry research report provides an in-depth and methodical assessment of regional and global markets, as well as the most recent service and product innovations and the global market’s predicted size.

Bluebird Bio's gene therapy for blood disorders approved by FDA panel

Advisers to the USFDA-backed Bluebird bio’s treatment for a rare blood disorder, signalling a vote of confidence in gene therapies and bolstering a company beset by regulatory setbacks.